These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 37274062)

  • 1. Study of tumor necrosis factor receptor in the inflammatory bowel disease.
    Souza RF; Caetano MAF; Magalhães HIR; Castelucci P
    World J Gastroenterol; 2023 May; 29(18):2733-2746. PubMed ID: 37274062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of bovine tumor necrosis factor alpha decoy receptors on cell death and inflammatory cytokine kinetics: potential for bovine inflammation therapy.
    Fujisawa S; Konnai S; Okagawa T; Maekawa N; Tanaka A; Suzuki Y; Murata S; Ohashi K
    BMC Vet Res; 2019 Feb; 15(1):68. PubMed ID: 30819151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
    Goll R; Moe ØK; Johnsen KM; Meyer R; Friestad J; Gundersen MD; Kileng H; Johnsen K; Florholmen JR
    BMC Gastroenterol; 2022 Nov; 22(1):464. PubMed ID: 36384462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TNF-
    Gane JM; Stockley RA; Sapey E
    J Immunol Res; 2016; 2016():1079851. PubMed ID: 27747245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment.
    Wen N; Zhao N; Xu H; Zhao Y; Ma J
    Ir J Med Sci; 2022 Oct; 191(5):2105-2111. PubMed ID: 34843071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
    Atreya R; Zimmer M; Bartsch B; Waldner MJ; Atreya I; Neumann H; Hildner K; Hoffman A; Kiesslich R; Rink AD; Rau TT; Rose-John S; Kessler H; Schmidt J; Neurath MF
    Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF Receptor 1 Promotes Early-Life Immunity and Protects against Colitis in Mice.
    Liu CY; Tam SS; Huang Y; Dubé PE; Alhosh R; Girish N; Punit S; Nataneli S; Li F; Bender JM; Washington MK; Polk DB
    Cell Rep; 2020 Oct; 33(3):108275. PubMed ID: 33086075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
    Biancheri P; Brezski RJ; Di Sabatino A; Greenplate AR; Soring KL; Corazza GR; Kok KB; Rovedatti L; Vossenkämper A; Ahmad N; Snoek SA; Vermeire S; Rutgeerts P; Jordan RE; MacDonald TT
    Gastroenterology; 2015 Nov; 149(6):1564-1574.e3. PubMed ID: 26170138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
    Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
    J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective role of tumor necrosis factor (TNF) receptors in chronic intestinal inflammation: TNFR1 ablation boosts systemic inflammatory response.
    Wang Y; Han G; Chen Y; Wang K; Liu G; Wang R; Xiao H; Li X; Hou C; Shen B; Guo R; Li Y; Chen G
    Lab Invest; 2013 Sep; 93(9):1024-35. PubMed ID: 23897411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
    Pedersen G
    Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel Disease.
    Potdar AA; Dube S; Naito T; Li K; Botwin G; Haritunians T; Li D; Casero D; Yang S; Bilsborough J; Perrigoue JG; Denson LA; Daly M; Targan SR; Fleshner P; Braun J; Kugathasan S; Stappenbeck TS; McGovern DPB
    Gastroenterology; 2021 Feb; 160(3):809-822.e7. PubMed ID: 33160965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study.
    Li J; Liu Z; Hu P; Wen Z; Cao Q; Zou X; Chen Y; Wang Y; Zhong J; Shen X; Demuth D; Fadeeva O; Xie L; Chen J; Qian J
    BMC Gastroenterol; 2022 Feb; 22(1):44. PubMed ID: 35120446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease.
    Tang R; Yang G; Zhang S; Wu C; Chen M
    Inflamm Bowel Dis; 2014 Nov; 20(11):1950-61. PubMed ID: 25208103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study.
    Balderramo D; Yamamoto-Furusho J; Ponce de León E; de María J; Zubiaurre I; Pedreira S; Lis C; Brion L; de Paula JA
    Gastroenterol Hepatol; 2024 Jan; 47(1):51-62. PubMed ID: 37062500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease.
    Noguchi M; Hiwatashi N; Liu Z; Toyota T
    Gut; 1998 Aug; 43(2):203-9. PubMed ID: 10189845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF-α and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohn's disease and ulcerative colitis.
    Owczarek D; Cibor D; Głowacki MK; Cieśla A; Mach P
    Pol Arch Med Wewn; 2012; 122(12):616-23. PubMed ID: 23160117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of C1q/TNF-related protein-3 in inflammatory bowel disease patients and its inverse association with inflammatory cytokines and insulin resistance.
    Mohamadinarab M; Ahmadi R; Gholamrezayi A; Rahvar F; Naghdalipour M; Setayesh L; Moradi N; Fadaei R; Chamani E; Tavakoli T; Esteghamati A
    IUBMB Life; 2020 Aug; 72(8):1698-1704. PubMed ID: 32311832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.
    Reinecker HC; Steffen M; Witthoeft T; Pflueger I; Schreiber S; MacDermott RP; Raedler A
    Clin Exp Immunol; 1993 Oct; 94(1):174-81. PubMed ID: 8403503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs.
    Na SY; Kim YS
    Korean J Intern Med; 2022 Sep; 37(5):906-919. PubMed ID: 35945034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.